MUR
45
-2
C
48
-2
PM
52
-16
KMX
64
6
EIX
59
-2
EXPD
45
-5
CINF
54
-2
CME
53
3
SHW
65
-3
AIG
65
-4
CAT
73
3
MCO
77
-3
OI
45
2
CPB
49
2
GILD
32
4
AZO
46
-4
ECL
84
-3
FTI
87
-4
GS
82
2
STI
49
14
MUR
45
-2
C
48
-2
PM
52
-16
KMX
64
6
EIX
59
-2
EXPD
45
-5
CINF
54
-2
CME
53
3
SHW
65
-3
AIG
65
-4
CAT
73
3
MCO
77
-3
OI
45
2
CPB
49
2
GILD
32
4
AZO
46
-4
ECL
84
-3
FTI
87
-4
GS
82
2
STI
49
14
Financhill
Back

Avenue Therapeutics Quote, Financials, Valuation and Earnings

Master the Market: The Formula for a 96.3% Win Rate Revealed!

Act now!
Sell
14

ATXI
Avenue Therapeutics

Last Price:
3.89
Seasonality Move:
-8.4%

7 Day Trial

ALL ACCESS PASS

$ 7

MarketBeat Alert: Strong sell signal just issued for these 20 stocks

Go here now to get free instant access to all 20 stocks to sell.

Avenue Therapeutics Price Quote

$3.89
+0.05 (+-1.77%)
(Updated: May 15, 2024 at 4:29 AM ET)

Avenue Therapeutics Key Stats

Sell
14
Avenue Therapeutics (ATXI) is a Sell
Day range:
$3.52 - $4.00
52-week range:
$3.52 - $93.75
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.28%
Volume:
68.6K
Avg. volume:
103.3K
1-year change:
-95.19%
Market cap:
$3.6M
Revenue:
$0
EPS:
$-285.75

How Much Does Avenue Therapeutics Make?

Data Unavailable

Is Avenue Therapeutics Growing As A Company?

Data Unavailable

Avenue Therapeutics Stock Price Performance

What Is Avenue Therapeutics 52-Week High & Low?

Avenue Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Avenue Therapeutics?

Is Avenue Therapeutics Cash Flow Positive?

  • What Is ATXI Cash Flow From Operations?
    Cash flow from operations (TTM) is -$9.5M
  • What Is Avenue Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $7.5M
  • What Is Avenue Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

Avenue Therapeutics Return On Invested Capital

Data Unavailable

Avenue Therapeutics Earnings Date & Stock Price

Avenue Therapeutics Competitors

  • Who Are Avenue Therapeutics's Competitors?
    Below is a list of companies who compete with Avenue Therapeutics or are related in some way:
    • Deciphera Pharmaceuticals Inc (DCPH)
    • Fortress Biotech Inc (FBIO)
    • Flora Growth Corp (FLGC)
    • NovaBay Pharmaceuticals Inc (NBY)
    • SINTX Technologies Inc (SINT)

Avenue Therapeutics Dividend Yield

Data Unavailable

Avenue Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: -79.24% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 1,228.13
Upside from Last Price: 31882.5%

Major Shareholders

  • How many ATXI shares are owned by institutional investors?
    3.8M ATXI shares are owned by institutional investors
  • How many ATXI shares are owned by insiders?
    0 ATXI shares are owned by insiders